Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose
단일 메신저 RNA 백신 용량을 사용하여 SARS-CoV-2 감염 후 산모 및 신생아 체액성 면역 강화
Article
Published on
Journal: American journal of obstetrics and gynecology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,
Journal: American journal of obstetrics and gynecology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,
[키워드] Affect
analyzed
anti SARS-CoV-2 antibody
anti-SARS-CoV-2 antibody
antibody
antibody levels
approach
BNT162b2
booster dose
boosting vaccine dose
Case-control
case-control study
collected
consecutive sample
convalescent
Cord blood
COVID-19
COVID-19 vaccination
determined by
dose
during pregnancy
Effect
first trimester
group
Guidance
Humoral immunity
increase in
Infection
Jerusalem
Messenger RNA
Mild symptom
mild symptoms
moderate
mother
naïve
Neonatal
Newborn
outcomes
pandemic
parturient
patients
polymerase chain
polymerase chain reaction
Postinfection
postinfection vaccine
Pregnancy
proportion
Protective
reported
robust
SARS-CoV-2
SARS-COV-2 infection
second trimester
selected
serum sample
serum samples
side
Side effects
single booster dose
single dose
Stage
study groups
tested
Umbilical cord
umbilical cord blood
umbilical cords
undetectable
vaccination
Vaccine
vaccine dose
vaccine during.
was determined
[DOI] 10.1016/j.ajog.2022.04.010 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ajog.2022.04.010 PMC 바로가기 [Article Type] Article